Direct medical costs associated with spinal muscular atrophy (SMA) are more than 50…
Steve Bryson, PhD
Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Steve Bryson, PhD
Researchers have found changes in the electrical activity between the brain and muscles in adults who had childhood…
Genetic analysis of 28 families with a member affected by spinal muscular atrophy…
An analysis of prenatal mice embryos carrying genetic mutations that cause severe cases of spinal…
Gene therapy that increased the production of a protein called DOK7 in a spinal muscular atrophy (SMA)…
Treatment with the molecule 4-aminopyridine (4-AP) failed to improve the motor function, endurance, and muscle strength…
Control Bionics has announced the launch of the GridPad Trilogy, an…
In cell- and mouse-based models of spinal muscular atrophy (SMA), reduced levels of…
Spinraza significantly eased fatigue in adults with spinal muscular atrophy (SMA)…
Continuing treatment for spinal muscular atrophy (SMA) is essential and should not be considered…